Table 3.

Predicted canonical pathways activated during the early response to PGF2α treatment.

	Ingenuity Canonical Pathways	z-score	P-value	Molecules
0.5 h	NRF2-mediated Oxidative Stress Response		1.41E-02	FOS, JUN, DNAJB1, JUNB
	Corticotropin Releasing Hormone Signaling		1.41E-02	FOS, JUN, NR4A1
	IGF-1 Signaling		1.41E-02	FOS, JUN, CYR61
	IL-17A Signaling in Gastric Cells		1.41E-02	FOS, JUN
	PI3K Signaling in B Lymphocytes		1.41E-02	FOS, JUN, ATF3
1 h	ILK Signaling	2.449	2.34E-02	FOS, JUN, SNAI1, MYC, SNAI2, RND3
	Cholecystokinin/Gastrin-mediated Signaling	2	3.89E-02	FOS, JUN, SRF, RND3
	HΜGB1 Signaling	2	2.45E-02	FOS, JUN, SERPINE1, PLAT, RND3
	Endothelin-1 Signaling	2	8.71E-02	FOS, JUN, MYC, EDNRB
	IL-8 Signaling	2	1.08E-01	FOS, JUN, ANGPT2, RND3
2 h	Cholecystokinin/Gastrin-mediated Signaling	2.646	2.99E-01	FOS, JUN, SRF, IL1B, IL1A, RND3, IL33
	Acute Phase Response Signaling	2.121	4.81E-01	FOS, JUN, IL1B, JAK2, SOCS3, IL1A, SERPINE1, IL33
	Toll-like Receptor Signaling	2	2.99E-01	FOS, JUN, IL1B, IL1A, TRAF1, IL33
	TGF-b Signaling	2	5.45E-01	FOS, JUN, INHBA, SERPINE1
	LPS/IL-1 Mediated Inhibition of RXR Function	2	7.43E-01	JUN, IL1B, PPARGC1B, IL1A, NR5A2, IL33
4 h	Death Receptor Signaling	−2.714	3.23E-01	IKBKG, TANK, CFLAR, NFKB1, PARP1, PARP4, CASP9, NFKBIA, ACIN1,TNKS, BIRC3, SPTAN1
	Integrin Signaling	−2.683	4.69E-01	ASAP1, TLN1, RRAS2, ITGAV, ITGA2, CAPN1, TSPAN4, PXN, PIK3C2B, MYL9,PIK3R1, GAB1, ITGA9, SOS1, PIK3CG, RHOG, PIK3CA, ARHGEF7, MAP2K2,TSPAN5, PPP1CB, PLCG1, ACTN4
	UVA-Induced MAPK Signaling	−2.496	1.64E-01	SMPD2, MTOR, PARP4, RRAS2, CASP9, PIK3C2B, PIK3R1, GAB1, TP53, TNKS,PIK3CG, FOS, RPS6KA5, PARP1, PIK3CA, PLCG1
	Retinoic acid Mediated Apoptosis Signaling	−2.449	1.78E-01	CFLAR, PARP1, PARP4, CASP9, RXRB, CRABP2, RARG, TNKS
	MIF Regulation of Innate Immunity	2.449	3.44E-01	FOS, LY96, NFKB1, CD14, NFKBIA, TP53